A three-gene signature for outcome in soft tissue sarcoma.
about
MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.Profiling of VEGFs and VEGFRs as prognostic factors in soft tissue sarcoma: VEGFR-3 is an independent predictor of poor prognosis.Gene expression identifies heterogeneity of metastatic behavior among high-grade non-translocation associated soft tissue sarcomas.A molecular prognostic model predicts esophageal squamous cell carcinoma prognosis.Combining targeted agents with modern radiotherapy in soft tissue sarcomas.A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGFA three-gene expression signature model for risk stratification of patients with neuroblastomaDetection of circulating tumor cell subpopulations in patients with head and neck squamous cell carcinoma (HNSCC).EGFR, FLT1 and heparanase as markers identifying patients at risk of short survival in cholangiocarcinomaIndividual profiling of circulating tumor cell composition in patients with non-small cell lung cancer receiving platinum based treatment.CT perfusion as an imaging biomarker in monitoring response to neoadjuvant bevacizumab and radiation in soft-tissue sarcomas: comparison with tumor morphology, circulating and tumor biomarkers, and gene expression.Circulating Tumor Cell Composition in Renal Cell Carcinoma.Inhibition of vascular endothelial growth factor A and hypoxia-inducible factor 1α maximizes the effects of radiation in sarcoma mouse models through destruction of tumor vasculaturePrognosis value of Hypoxia-inducible factor-1α expression in patients with bone and soft tissue sarcoma: a meta-analysis.Artificial neural network classifier predicts neuroblastoma patients' outcomeHypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas.Characterization of a variety of neutralizing anti-heparin-binding epidermal growth factor-like growth factor monoclonal antibodies by different immunization methodsPrognostic microRNAs modulate the RHO adhesion pathway: A potential therapeutic target in undifferentiated pleomorphic sarcomasFormation and repair kinetics of Pt-(GpG) DNA adducts in extracted circulating tumour cells and response to platinum treatment.Hypoxia-inducible factors: mediators of cancer progression; prognostic and therapeutic targets in soft tissue sarcomas.The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets.Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α.Molecular Predictors of Radiotherapy Response in Sarcoma.Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapyTumour-associated macrophages correlate with poor prognosis in myxoid liposarcoma and promote cell motility and invasion via the HB-EGF-EGFR-PI3K/Akt pathways.Individual profiling of circulating tumor cell composition and therapeutic outcome in patients with hepatocellular carcinoma.The Genomic Grade Index predicts post-operative clinical outcome in patients with soft tissue sarcoma.
P2860
Q33651005-E40D4355-2E4D-4DF0-BCB0-8B0CBBCDC73CQ33778580-C8CF2E24-A286-4B7E-BCDA-653551011E31Q33847814-57EACE5A-6472-426E-A60B-AD61C3F36ED0Q34084021-E0E2CEB5-003D-4CBE-AC25-EA3EDC7FB955Q34396047-C1047163-F884-4402-8F5D-9796EEB4BF30Q34517448-43411BE0-E671-4A68-8261-2F80415FC8AFQ34559142-5223272B-0163-4F24-8975-25FE0649E7CEQ34640026-EB343B40-DF2B-4B04-9F0C-C640E311795AQ34738001-692F5CA9-D5D3-4EBC-B934-610FB9923825Q35200511-443D72F0-5D78-44D2-9F3A-AD6AD6B07B66Q35776891-FC42D357-E55B-4219-B9C9-8380002A2407Q35996235-7BBEC76D-6978-4D66-8922-47C3278E4AC5Q36027155-CED03AA0-76FF-436A-AC0B-8E6FE6C66AECQ36126048-AE913939-97C4-413F-8D0E-9FA0B235CE91Q36276501-A6D0C22C-FC52-49C3-92D7-E30D043C88D3Q36286658-69E21BAD-788B-41B6-A6AB-5790DEEA75C4Q36411849-7540C952-5160-4146-BB6A-567358807D0CQ36629530-0BD87E79-E5C0-4A44-9500-0B537D228A45Q37185747-0CD9126F-44B0-4D8C-9767-19A75E805EF3Q38161730-8C876FCB-B4D2-4577-BCD0-443C95ACAE49Q38252537-AD16E58E-5BDC-489C-BAE9-EBB63CE3E67DQ38496656-AD79143E-5CC1-47BD-8EB1-FCA9CE6F4091Q38682324-F771116A-0BF0-4A05-919A-146EB4EF4467Q38936104-0BC7BE96-77C9-4791-81B0-7060943E8852Q39984948-FB7BEF66-B4DB-49ED-9F8A-3203019C51B3Q42275473-63AE2B0F-4760-4647-9CDC-65322CD3C1F5Q43065749-FF20366B-4F38-4420-96BB-44AF393CCD6CQ47720588-22D7DD66-7466-40F6-BED2-30CFE1B75921
P2860
A three-gene signature for outcome in soft tissue sarcoma.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A three-gene signature for outcome in soft tissue sarcoma.
@ast
A three-gene signature for outcome in soft tissue sarcoma.
@en
type
label
A three-gene signature for outcome in soft tissue sarcoma.
@ast
A three-gene signature for outcome in soft tissue sarcoma.
@en
prefLabel
A three-gene signature for outcome in soft tissue sarcoma.
@ast
A three-gene signature for outcome in soft tissue sarcoma.
@en
P2093
P1476
A three-gene signature for outcome in soft tissue sarcoma.
@en
P2093
Andreas-Claudius Hoffmann
Kathleen D Danenberg
Peter V Danenberg
Peter Wuerl
P304
P356
10.1158/1078-0432.CCR-08-2534
P407
P577
2009-08-11T00:00:00Z